The PEARL 8.0 Post-Approval Study

NCT01845103 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-10-06

Study results available
· View outcomes & findings →

Summary

This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery System. The purpose of this study is to demonstrate that the 30 day mortality rate among patients who are treated with this device is less than the historical rate plus a non-inferiority margin.

Conditions

  • Class IV Angina

Sponsors & Collaborators

  • Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.

    lead INDUSTRY

Principal Investigators

  • Scott B Capps, MS · CryoLife, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01845103 on ClinicalTrials.gov